Marshall Fordyce sold $754k of VERA
PRESIDENT AND CEO at Vera Therapeutics, Inc.. 17,500 shares at an average of $43.07, traded Dec 18, 2024, filed Dec 20, 2024.
Score components
- +25RoleCEO
- +22Trade size$754k at market
- +5Share of holdings soldSold 20% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029964, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | MOption exercise Class A Common Stock10b5-1 | +3,772 | $2.90 | $11k | 89,714 | Dec 20, 2024 |
| Dec 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,772 | $41.33 | $156k | 85,942 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Class A Common Stock10b5-1 | +2,195 | $2.90 | $6,358 | 88,137 | Dec 20, 2024 |
| Dec 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -2,195 | $42.35 | $93k | 85,942 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Class A Common Stock10b5-1 | +5,023 | $2.90 | $15k | 90,965 | Dec 20, 2024 |
| Dec 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -5,023 | $43.52 | $219k | 85,942 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Class A Common Stock10b5-1 | +4,635 | $2.90 | $13k | 90,577 | Dec 20, 2024 |
| Dec 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -4,635 | $44.03 | $204k | 85,942 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Dec 20, 2024 |
| Dec 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $43.81 | $82k | 85,942 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Class A Common Stock10b5-1 | +57,661 | $2.90 | $167k | 143,603 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,625 | $0.00 | $0 | 686,087 | Dec 20, 2024 |
| Dec 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 684,212 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -57,661 | $0.00 | $0 | 626,551 | Dec 20, 2024 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 24Weak | VERAsell Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% | |
| 36Weak | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $250k 5,882 shares | - | |
| 7Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $453k 10,000 shares | -31% | |
| 14Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $400k 10,000 shares | -31% | |
| 40Moderate | Vera Therapeutics, Inc. | Jason S Carter Chief Legal Officer | $107k 3,864 shares | -7% | |
| 30Weak | Vera Therapeutics, Inc. | Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR | $436k 15,000 shares | -24% | |
| 51Moderate | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $5.3M 250,000 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.